TCRR - TCR2 Therapeutics GAAP EPS of -$1.03 misses by $0.34
2023-05-11 07:52:15 ET
- TCR2 Therapeutics press release ( NASDAQ: TCRR ): Q1 GAAP EPS of -$1.03 misses by $0.34 .
- TCR 2 ended the first quarter of 2023 with $110.3 million in cash, cash equivalents, and investments compared to $149.2 million as of December 31, 2022.
For further details see:
TCR2 Therapeutics GAAP EPS of -$1.03 misses by $0.34